Level Biotechnology Inc.

TPEX:3118 Stock Report

Market Cap: NT$1.0b

Level Biotechnology Past Earnings Performance

Past criteria checks 4/6

Level Biotechnology has been growing earnings at an average annual rate of 4.8%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 0.5% per year. Level Biotechnology's return on equity is 12.1%, and it has net margins of 9.1%.

Key information

4.8%

Earnings growth rate

4.8%

EPS growth rate

Healthcare Industry Growth9.1%
Revenue growth rate0.5%
Return on equity12.1%
Net Margin9.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Some Investors May Be Worried About Level Biotechnology's (GTSM:3118) Returns On Capital

Apr 27
Some Investors May Be Worried About Level Biotechnology's (GTSM:3118) Returns On Capital

Calculating The Fair Value Of Level Biotechnology Inc. (GTSM:3118)

Mar 16
Calculating The Fair Value Of Level Biotechnology Inc. (GTSM:3118)

Here's What You Should Know About Level Biotechnology Inc.'s (GTSM:3118) 3.6% Dividend Yield

Feb 14
Here's What You Should Know About Level Biotechnology Inc.'s (GTSM:3118) 3.6% Dividend Yield

Does Level Biotechnology's (GTSM:3118) Returns On Capital Reflect Well On The Business?

Jan 24
Does Level Biotechnology's (GTSM:3118) Returns On Capital Reflect Well On The Business?

Level Biotechnology Inc.'s (GTSM:3118) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Jan 03
Level Biotechnology Inc.'s (GTSM:3118) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Calculating The Intrinsic Value Of Level Biotechnology Inc. (GTSM:3118)

Dec 16
Calculating The Intrinsic Value Of Level Biotechnology Inc. (GTSM:3118)

Here's Why We Think Level Biotechnology's (GTSM:3118) Statutory Earnings Might Be Conservative

Nov 28
Here's Why We Think Level Biotechnology's (GTSM:3118) Statutory Earnings Might Be Conservative

Revenue & Expenses Breakdown

How Level Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:3118 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247166514813
30 Jun 246976214413
31 Mar 246956614113
31 Dec 236616313814
30 Sep 236546013214
30 Jun 236336213014
31 Mar 236206412614
31 Dec 225935812414
30 Sep 225695712714
30 Jun 226016213015
31 Mar 226326113615
31 Dec 216776813915
30 Sep 217287413815
30 Jun 217167013514
31 Mar 217016913314
31 Dec 206725813214
30 Sep 206485012914
30 Jun 206414812713
31 Mar 206354712514
31 Dec 196394712614
30 Sep 196464712414
30 Jun 196514512415
31 Mar 196444112415
31 Dec 186293912314
30 Sep 186194612413
30 Jun 185794512112
31 Mar 185835711811
31 Dec 175786811512
30 Sep 175437211112
30 Jun 175377510913
31 Mar 175126510714
31 Dec 165146310614
30 Sep 165046110514
30 Jun 165236910414
31 Mar 165307810515
31 Dec 155207810315
30 Sep 155408510415
30 Jun 155248010415
31 Mar 155267710214
31 Dec 145337710414
30 Sep 145157110014
30 Jun 145357010015
31 Mar 145276610116

Quality Earnings: 3118 has high quality earnings.

Growing Profit Margin: 3118's current net profit margins (9.1%) are lower than last year (9.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 3118's earnings have grown by 4.8% per year over the past 5 years.

Accelerating Growth: 3118's earnings growth over the past year (9%) exceeds its 5-year average (4.8% per year).

Earnings vs Industry: 3118 earnings growth over the past year (9%) exceeded the Healthcare industry 7.3%.


Return on Equity

High ROE: 3118's Return on Equity (12.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 11:36
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Level Biotechnology Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution